Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
B BLOOD AND BLOOD FORMING ORGANS
B02 ANTIHEMORRHAGICS
B02B VITAMIN K AND OTHER HEMOSTATICS
B02BX Other systemic hemostatics
B02BX07 Lusutrombopag
D10476 Lusutrombopag (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Products and Modifiers
Blood Products and Modifiers, Other
Blood Products and Modifiers, Micellaneous
Lusutrombopag
D10476 Lusutrombopag (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
33 Blood and body fluid agents
339 Miscellaneous
3399 Others
D10476 Lusutrombopag (JAN/USAN/INN)
Drug groups [BR:br08330]
Metabolizing enzyme substrate
DG02978 CYP4A11 substrate
D10476 Lusutrombopag
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokine receptors
CSF and other factor receptors
MPL (TPOR, CD110)
D10476 Lusutrombopag (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D10476
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D10476
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D10476
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D10476
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D10476
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D10476